

Datasheet: PIP048A BATCH NUMBER 180209

Description:	RECOMBINANT DENGUE VIRUS TYPE 2 NS1 ANTIGEN	
Name:	DENGUE VIRUS TYPE 2 NS1 ANTIGEN	
Other names:	DENV2 NS1 ANTIGEN	
Format:	Rec. Protein	
Product Type:	Recombinant Protein	
Quantity:	100 µg	

Product Details

Applications	This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> .					
		Yes	No	Not Determined	Suggested Dilution	
	ELISA	-				
	Where this product has not been tested for use in a particular technique this does no necessarily exclude its use in such procedures. Suggested working dilutions are give a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.					
Target Species	Viral					
Product Form	Purified recombinant pro	otein with a	a C-termir	nal 6 x His-tag - liquid		
Preparation	Recombinant dengue vir expressed in 293 human		be 2 NS1	protein, sequence stra	in Thailand/16681/84,	
Buffer Solution	Dulbecco's phosphate bu	uffered sal	ine			
Preservative Stabilisers	None present					
Approx. Protein Concentrations	Approximate protein con	centration	0.54 mg/	/ml		
Specificity	Recombinant dengue v virus serotype 2 (DENV2 (DENV1-4) antigenically <i>Flaviviridae</i> family, genus	2), non-stru distinct, c	uctural pr losely rela	otein 1 (NS1). DENV2 ated viral serotypes be	is one of four longing to the	

humans.

Informati		
	nd Safety ion	Material Safety Datasheet documentation #10286 available at: https://www.bio-rad-antibodies.com/SDS/PIP048A 10286
Acknowle	edgements	His-tag is a registered trademark of EMD Biosciences.
Guarante	90	12 months from date of despatch
Storage		Store at -70°C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this m denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.
Further F	Reading	1. Guzman, M.G. <i>et al.</i> (2010) Dengue: a continuing global threat. <u>Nat Rev Microbiol. 8</u> (12 Suppl): S7-16.
Purity		>95% by SDS PAGE analysis
		Recombinant DENV2 NS1 antigen is presented in its native folded state complete with post-translational modifications, delivering optimal antigenicity and making it suitable for use in vaccine research and serology-based assays.
		The NS1 glycoprotein is essential for viral replication and viability, and since this protein secreted into the bloodstream, tests have been developed to diagnose DENV infections using NS1, including antigen-capture ELISA, lateral flow antigen detection, and the measurement of NS1-specific IgM and IgG responses (Guzman, M.G. <i>et al.</i> 2010).
		tropical and subtropical regions. There is currently no vaccine to prevent, or effective anti-viral drugs to treat, dengue virus infection. In many cases infection is assymptomati and the majority of individuals who get ill only suffer the mild, non-specific febrile symptoms characteristic of dengue fever (DF). Only a minority of infections result in severe disease, manifesting as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). Dengue virus infection gives lifelong immunity to the serotype in question but subsequent infection with another serotype may increase the likelihood of severe disease.

Page 2 of 3

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint